Biliary tract cancer
Conditions
Interventions
Immunotherapy + albumin-bound paclitaxel:No
Sponsors
the Second Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Histologically or cytologically confirmed locally advanced or metastatic biliary tract malignancies; (2) Age between 18 and 75 years old, with a life expectancy of >=3 months; (3) Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; (4) Disease progression or intolerance after prior systemic chemotherapy; (5) No prior treatment with taxane medications, including but not limited to paclitaxel, paclitaxel liposome, albumin-bound paclitaxel, and docetaxel; (6) Measurable disease according to RECIST version 1.1 criteria.
Exclusion criteria
Exclusion criteria: (1) Severe comorbidities such as severe hepatic dysfunction or renal insufficiency. (2) History of allergy or severe adverse reactions to other taxane drugs. (3) Pregnant or nursing women. (4) Uncontrolled serious complications such as brain metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall Survival;Treatment-related adverse events; | — |
Countries
China
Contacts
Public ContactYe Mao
the Second Affiliated Hospital of Nanchang University
Outcome results
None listed